Baker McKenzie has acted as legal counsel in connection with the sale of Cyclopharma to the Curium group, excluding existing R&D activities and the international operations of Cyclopharma which have been taken over by the Denos group, the seller and majority shareholder.
Created in 2000, the French pharmaceutical laboratory, Cyclopharma specialises in molecular imaging, develops and produces diagnostic PET tracers. This technique is used notably in oncology, neurology and cardiology sectors. The company currently has 100 employees.
Curium is a world leader in the supply of nuclear medicine solutions. With more than 50 production sites throughout Europe and the United States, and an industrial experience of over 100 years, Curium supplies its products to more than 14 million patients globally in SPECT and TEP mode and in therapy.
This merger between two major players in the PET imaging sector will make it possible to improve coverage of the French territory and provide imaging solutions to close to 320 000 patients in France thanks to the combined Curium and Cyclopharma networks. The acquisition will allow Curium to make use of the expertise of the Cyclopharma teams in the development of new products.
Baker McKenzie advised Cyclopharma with a team led by Raphaële-François Poncet, partner, assisted by Antoine Caillard, counsel, and Solenne Gilles and Paul Nury, associates, in M&A. Edouard de Rancher, partner, and Johanna da Costa, associate, worked on tax law aspects. Julie Yeni, partner, and Isabelle Giusti, associate, contributed at the level of pharmaceutical law.